New investigational drugs for androgenetic alopecia

Expert Opinion on Investigational Drugs

Volumn 22, Issue 5, 2013, Pages 573-589

  Valente Duarte De Sousa, Isabel Cristina ^a   Tosti, Antonella ^b  

^a Private Dermatology Practice   (Mexico)

^b UNIVERSITY OF MIAMI HOSPITAL   (United States)

Author keywords

5 alfa reductase inhibitors; Androgenetic alopecia; Dutasteride; Finasteride; Hair stimulating complex; Minoxidil; Platelet rich plasma; Prostaglandins; Stem cells; Wnt signaling

Indexed keywords

BETA CATENIN; BIOTIN; COLECALCIFEROL; CORTODOXONE; DEXPANTHENOL; DUTASTERIDE; FINASTERIDE; LATANOPROST; LITHIUM GLUCONATE; MINOXIDIL; NITRIC OXIDE; PROSTAGLANDIN; PYRIDOXINE; ROXITHROMYCIN; SPIRONOLACTONE; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

BASAL CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EPIDERMIS CELL; HAIR FOLLICLE; HAIR GROWTH; HAIR TRANSPLANTATION; HEADACHE; HUMAN; INJECTION PAIN; MALE TYPE ALOPECIA; NONHUMAN; PRURITUS; REVIEW; STEM CELL; THROMBOCYTE RICH PLASMA; WNT SIGNALING PATHWAY;

5-ALPHA REDUCTASE INHIBITORS; ALOPECIA; ANDROGEN ANTAGONISTS; ANIMALS; DRUGS, INVESTIGATIONAL; HAIR; HUMANS; PLATELET-RICH PLASMA; PROSTAGLANDINS; WNT PROTEINS;

EID: 84876211904     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.784743     Document Type: Review

References (84)

1. Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011;164(1):5-15
2. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999;341(7):491-7
3. McElwee KJ, Shapiro JS. Promising therapies for treating and/or preventing androgenetic alopecia. Skin Therapy Lett 2012;17(6):1-4
4. Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and men. J Dtsch Dermatol Ges 2011;9(Suppl 6):S1-57
5. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004;150(2):186-94
6. Davies GC, Thornton MJ, Jenner TJ, et al. Novel and established potassium channel openers stimulate hair growth in vitro: implications for their modes of action in hair follicles. J Invest Dermatol 2005;124(4):686-94
7. Michelet JF, Commo S, Billoni N, et al. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol 1997;108(2):205-9
8. Kvedar JC, Baden HP, Levine L. Selective inhibition by minoxidil of prostacyclin production by cells in culture. Biochem Pharmacol 1988;37(5):867-74
9. Garza LA, Yang CC, Zhao T, et al. Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. J Clin Invest 2011;121(2):613-22
10. Mysore V. Finasteride and sexual side effects. Indian Dermatol Online J 2012;3(1):62-5
11. Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry 2012;73(9):1220-3
12. Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol 2009;75(1):47-51
13. Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0. 1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai 2012;95(10):1312-16
14. Madheswaran T, Baskaran R, Thapa RK, et al. Design and in vitro evaluation of finasteride-loaded liquid crystalline nanoparticles for topical delivery. AAPS PharmSciTech 2013;14(1):45-52
15. Caserini M, Radicioni M, Annoni O, Palmieri R. Pharmacokinetics and pharmacodynamics of finasteride topical solution after single and repeated dose in subjects with androgenetic alopecia. 42nd Annual ESDR Meeting; 18 -22 September 2012; Venice
16. Moftah N, Moftah N, Abd-Elaziz G, et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrastructural evaluation. J Eur Acad Dermatol Venereol 2012;published online 6 April 2012; doi:10. 1111/j. 1468-3083. 2012. 04535. x
17. Duque-Estrada B, Vicenzi C, Misciali C, Tosti A. Alopecia secondary to mesotherapy. J Am Acad Dermatol 2009;61(4):707-9
18. Kadry R, Hamadah I, Al-Issa A, et al. Multiple scalp abscess with subcutaneous fat necrosis and scarring alopecia as a complication of scalp mesotherapy. J Drugs Dermatol 2008;7(1):72-3
19. Sharma P, Jain D, Maithani M, et al. Development and characterization of dutasteride bearing liposomal systems for topical use. Curr Drug Discov Technol 2011;8(2):136-45
20. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124(4):544-7
21. Smith S, Fagien S, Whitcup SM, et al. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol 2012;66(5):801-6
22. Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol 2005;14(5):323-8
23. Roenigk HH Jr. New topical agents for hair growth. Clin Dermatol 1988;6(4):119-21
24. Available from: www. clinicaltrials. gov/ct2/results?term= androgenetic+alopecia +treatment&Search=Search [Last accessed 24 February 2013]
25. Blume-Peytavi U, Lonnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebocontrolled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0. 1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol 2012;66(5):794-800
26. Digiuni M, Manni G, Vetrugno M, et al. An evaluation of Therapeutic Noninferiority of 0. 005% lanatoprost ophthalmic solution and Xalatan in patients with glaucoma or ocular hypertension. J Glaucoma 2012; [Epub ahead of print]
27. Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med 2012;4(126):126ra34
28. Colombe L, Michelet JF, Bernard BA. Prostanoid receptors in anagen human hair follicles. Exp Dermatol 2008;17(1):63-72
29. Pettipher R, Vinall SL, Xue L, et al. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther 2012;340(2):473-82
30. Jones RL, Giembycz MA, Woodward DF. Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 2009;158(1):104-45
31. Nelson AM, Loy DE, Lawson JA, et al. Prostaglandin D(2) inhibits wound-induced hair follicle neogenesis through the receptor, Gpr44. J Invest Dermatol 2012; published online 29 November 2012; doi: 10. 1038/jid. 2012. 398
32. Colombe L, Vindrios A, Michelet JF, Bernard BA. Prostaglandin metabolism in human hair follicle. Exp Dermatol 2007;16(9):762-9
33. Blume-Peytavi U, Hillmann K, Dietz E, et al. A randomized, single-blind of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 2011;65(6):1126-34
34. Fu J, Hsu W. Epidermal Wnt controls hair follicle induction by orchestrating dynamic signaling crosstalk between the epidermis and dermis. J Invest Dermatol 2013;13(4):890-98
35. Huang S, Zhu X, Liu Y, et al. Wls is expressed in the epidermis and regulates embryonic hair follicle induction in mice. PLoS One 2012;7(9):e45904
36. Bielefeld KA, Amini-Nik S, Alman BA. Cutaneous wound healing: recruiting developmental pathways for regeneration. Cell Mol Life Sci 2012; [Epub ahead of print]
37. Zhang Y, Tomann P, Andl T, et al. Reciprocal requirements for EDA/EDAR/NF-kappaB and Wnt/beta-catenin signaling pathways in hair follicle induction. Dev Cell 2009;17(1):49-61
38. Andl T, Reddy ST, Gaddapara T, Millar SE. WNT signals are required for the initiation of hair follicle development. Dev Cell 2002;2(5):643-53
39. Ito M, Yang Z, Andl T, et al. Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature 2007;447(7142):316-20
40. Kishimoto J, Burgeson RE, Morgan BA. Wnt signaling maintains the hair-inducing activity of the dermal papilla. Genes Dev 2000;14(10):1181-5
41. Millar SE. Molecular mechanisms regulating hair follicle development. J Invest Dermatol 2002;118(2):216-25
42. Shimizu H, Morgan BA. Wnt signaling through the [beta]-catenin pathway is sufficient to maintain, but not restore, anagen-phase characteristics of dermal papilla cells. J Investig Dermatol 2004;122(2):239-45
43. Chen D, Jarrel A, Guo C, et al. Dermal beta-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation. Development 2012;139(8):1522-33
44. Schmidt-Ullrich R, Paus R. Molecular principles of hair follicle induction and morphogenesis. Bioessays 2005;27(3):247-61
45. Leirós GJ, Attoresi AI, Balañá ME. Hair follicle stem cell differentiation is inhibited through cross-talk between Wnt/beta-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. Br J Dermatol 2012;166(5):1035-42
46. Available from: http://www. follicabio. com/content/science-and- technology/[Last accessed 25 February 2013]
47. Available from: https://www. clinicaltrialsregister. eu/ctr-search/trial/ 2009-018191-34/DE [Last accessed 25 February 2013]
48. Gurvich N, Klein PS. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther 2002;96(1):45-66
49. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 2007;64(16):2090-103
50. Lee SH, Yoon J, Shin SH, et al. Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. PLoS One 2012;7(4):e34152
51. Zimber MP, Ziering C, Zeigler F, et al. Hair regrowth following a Wnt-and follistatin containing treatment: safety and efficacy in a first-in-man Phase I clinical trial. J Drugs Dermatol 2011;10(11):1308-12
52. Available from: http://www. histogen. com/technology. htm [Last accessed 24 February 2013]
53. Cegielski M, Izykowska I, Chmielewska M, et al. Characteristics of MIC-1 antlerogenic stem cells and their effect on hair growth in rabbits. In Vivo 2013;27(1):97-106
54. Toyoshima KE, Asakawa K, Ishibashi N, et al. Fully functional hair follicle regeneration through the rearrangement of stem cells and their niches. Nat Commun 2012;3:784
55. Available from: http://www. aderansresearch. com/ari-science. html [Last accessed 24 February 2013]
56. Available from: http://www. replicel. com/our-science/research-findings/ [Last accessed 24 February 2013]
57. Adams JU. Raising hairs. Nat Biotechnol 2011;29(6):474-6
58. Available from: http://www. replicel. com/wp-content/uploads/ replicelfacts-Dec2012. pdf [Last accessed 24 February 2013]
59. Available from: http://www. replicel. com/wp-content/uploads/2012/Phase- I-IIa-Interim-Results. pdf [Last accessed 24 February 2013]
60. Eppley BL, Pietzak WS, Blanton M. Platelet-rich plasma: a review of biology and applications in plastic surgery. Plast Reconstr Surg 2006;118(6):147e-59e
61. Li ZJ, Choi HI, Choi DK, et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg 2012;38(7 Pt 1):1040-6
62. Uebel CO, da Silva JB, Cantarelli D, Martins P. The role of platelet plasma growth factors in male pattern baldness surgery. Plast Reconstr Surg 2006;118(6):1458-66
63. Takikawa M, Nakamura S, Nakamura S, et al. Enhanced effect of platelet-rich plasma containing a new carrier on hair growth. Dermatol Surg 2011;37(12):1721-9
64. Kang JS, Zheng Z, Choi MJ, et al. The effect of CD34+ cell-containing autologous platelet-rich plasma injection on pattern hair loss: a preliminary study. J Eur Acad Dermatol Venereol 2012;published online 20 December 2012; doi:10. 1111/jdv. 12062 [Epub ahead of print]
65. Available from: http://kasiakresearch. com/home. html [Last accessed 24 February 2013]
66. Available from: http://www. clinicaltrials. gov/ct2/show/NCT00175617? term=antiandrogens&rank=8 [Last accessed 26 February 2013]
67. Trifu V, Tiplica GS, Naumescu E, et al. Cortexolone 17 alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs placebo and tretinoin 0. 05% cream. Br J Dermatol 2011;165(1):177-83
68. Available from: http://www. clinicaltrials. gov/ct2/show/NCT01631474? term=cortexolone+17apropionate& rank=1 [Last accessed 26 February 2013]
69. Yang CC. Calvitron automated hair transplant system in alopecia treatment: a case report. Kaohsiung J Med Sci 2003;19(9):470-4
70. Brandy DA. Conventional grafting combined with minigrafting: a new approach. J Dermatol Surg Oncol 1987;13(1):60-3
71. Rassman WR, Bernstein RM, McClellan R, et al. Follicular unit extraction: minimally invasive surgery for hair transplantation. Dermatol Surg 2002;28(8):720-8
72. Available from: http://restorationrobotics. com/the-artas-advantage/ commitment-toclinical-excellence/[Last accessed 24 February 2013]
73. Takahashi H, Suzuki Y, Miyauchi Y, et al. Roxithromycin decreases ultraviolet B irradiation-induced reactive oxygen intermediates production and apoptosis of keratinocytes. J Dermatol Sci 2004;34(1):25-33
74. Inui S, Nakajima T, Fukuzato Y, et al. Potential anti-androgenic activity of roxithromycin in skin. J Dermatol Sci 2001;27(2):147-51
75. Sawaya ME, Keane RW, Blume-Peytavi U, et al. Androgen responsive genes as they affect hair growth. Eur J Dermatol 2001;11(4):304-8
76. Trueb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol 2002;37(8-9):981-90
77. Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol 2001;45(3 Suppl):S81-6
78. Ito T, Fukamizo H, Ito N, et al. Roxithromycin antagonizes catagen induction in murine and human hair follicles: implication of topical roxithromycin as hair restoration reagent. Arch Dermatol Res 2009;301(5):347-55
79. Amor KT, Rashid RM, Mirmirani P. Does D matter? The role of vitamin D in hair disorders and hair follicle cycling. Dermatol Online J 2010;16(2):3
80. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13(3):325-49
81. Reichrath J, Schilli M, Kerber A, et al. Hair follicle expression of 1, 25-dihydroxyvitamin D3 receptors during the murine hair cycle. Br J Dermatol 1994;131(4):477-82
82. Aoi N, Inoue K, Chikanishi T, et al. 1alpha, 25-dihydroxyvitamin D3 modulates the hair-inductive capacity of dermal papilla cells: therapeutic potential for hair regeneration. Stem Cells Transl Med 2012;1(8):615-26
83. Yoshizawa T, Handa Y, Uematsu Y, et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997;16(4):391-6
84. Vegesna V, O'Kelly J, Uskokovic M, et al. Vitamin D3 analogs stimulate hair growth in nude mice. Endocrinology 2002;143(11):4389-96